HCA (HCA) SVP & Controller receives 2,560 stock appreciation rights grant

Rhea-AI Filing Summary

HCA Healthcare, Inc. reported that its SVP & Controller, Christopher F. Wyatt, received a grant of stock appreciation rights on January 29, 2026. The award covers 2,560 stock appreciation rights with an exercise price of $482.53 per share.

These stock appreciation rights vest in four equal annual installments beginning on January 29, 2027, and are exercisable through January 29, 2036. Following this grant, Wyatt beneficially holds 2,560 derivative securities directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wyatt Christopher F.

(Last) (First) (Middle)

ONE PARK PLAZA

(Street)

NASHVILLE TN 37203

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
HCA Healthcare, Inc. [ HCA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP & Controller

3. Date of Earliest Transaction (Month/Day/Year)
01/29/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Appreciation Right	$482.53	01/29/2026		A		2,560		01/29/2027(1)	01/29/2036	Common Stock	2,560	$0	2,560	D

Explanation of Responses:

1. The stock appreciation rights vest in four equal annual installments beginning on January 29, 2027.

	/s/ Kevin A. Ball, Attorney-in-Fact	02/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did HCA (HCA) disclose in this Form 4 filing?

HCA disclosed that SVP & Controller Christopher F. Wyatt received 2,560 stock appreciation rights. The grant was made on January 29, 2026, as a derivative equity award tied to HCA common stock, reflecting part of his executive compensation package.

How many stock appreciation rights did HCA executive Christopher Wyatt receive?

Christopher Wyatt received 2,560 stock appreciation rights linked to HCA common stock. These rights provide value based on stock price appreciation above the exercise price, aligning his potential compensation with future HCA share performance over the vesting and exercise period.

What is the exercise price of the HCA stock appreciation rights granted?

The stock appreciation rights granted to Christopher Wyatt have an exercise price of $482.53 per share. This means potential value arises only if HCA’s stock trades above $482.53 during the exercisable period, tying the award’s benefit directly to future stock price performance.

When do the HCA stock appreciation rights granted to Christopher Wyatt vest?

The stock appreciation rights vest in four equal annual installments beginning on January 29, 2027. This multi-year vesting schedule encourages longer-term alignment between the executive’s incentives and HCA’s performance, as full vesting occurs gradually over four years.

What is the expiration date for Christopher Wyatt’s HCA stock appreciation rights?

The stock appreciation rights granted to Christopher Wyatt expire on January 29, 2036. He can exercise vested rights between the first vesting date in 2027 and this 2036 expiration, subject to HCA’s applicable equity plan terms and any insider trading or company policies.

Is Christopher Wyatt’s ownership in these HCA derivative securities direct or indirect?

Christopher Wyatt’s ownership of the 2,560 stock appreciation rights is reported as direct. The filing does not attribute the award to any trust, LLC, or other entity, indicating the derivative securities are directly held as part of his executive compensation.